Journal of Endocrinological Investigation

, Volume 26, Issue 9, pp 814–822 | Cite as

Regulation of body composition by androgens

Article

Abstract

Human body can be viewed simplisti-cally as being composed of fat-free and fat mass. With more sophisticated techniques, body composition can be broken down into fat mass, skeletal muscle mass, nonmuscle lean mass, visceral mass and bone mineral content. Similarly, it is possible to obtain estimates of total body water and intracellular and extracellular water contents.

Regardless of the model of body composition assessment, it is evident that androgens are important determinants of body composition; there is no body compartment that is not directly or indirectly affected by androgens.

The effects of androgens on skeletal muscle mass have received the greatest attention in recent literature; however, growing body of evidence suggests that androgens also regulate fat mass, bone mineral content, nonmuscle soft tissues and body water.

Key-word

Body composition androgen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months treatment on markers of bone formation and resorption. J Bone Miner Res 1997, 12: 472–8.PubMedCrossRefGoogle Scholar
  2. Bakhshi V, Elliott M, Gentili A, Godschalk M, Mulligan T. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc 2000, 48: 550–3PubMedGoogle Scholar
  3. Bardin CW. The anabolic action of testosterone. N Engl J Med 1996, 335: 52–3.PubMedCrossRefGoogle Scholar
  4. Barrett-Connors E, Khaw K-T. Endogenous sex-hormones and cardiovascular disease in men. A prospective population-based study Circulation 1988, 78: 539–45.Google Scholar
  5. Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999, 84: 3681–5.PubMedGoogle Scholar
  6. Bartsch W, Krieg M, Voigt KD. Quantitation of endogenous testosterone, 5-alpha-dihydrotestosterone and 5-alpha-androstane-3-alpha, 17-beta-diol in subcellular fractions of the prostate, bulbocavernosus/levator ani muscle, skeletal muscle, and heart muscle of the rat. J Steroid Biochem 1980, 13: 259–67.PubMedCrossRefGoogle Scholar
  7. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico [published erratum appears in: Am J Epidemio 1999, 149: 1161]. Am J Epidemiol 1998, 147: 755–63.PubMedCrossRefGoogle Scholar
  8. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Longterm effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997, 82: 2386–90.PubMedCrossRefGoogle Scholar
  9. Bellido T, Jilka RL, Boyce BF, et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens: the role of androgen receptor. J Clin Invest 1995, 95: 2886–95.PubMedCentralPubMedCrossRefGoogle Scholar
  10. Bhasin S, Javanbakht M. Can androgen therapy replete ean body mass and improve muscle function in wasting associated with human immunodeficiency virus infection? J Parenter Enteral Nutr 1999, 23: S195–201.CrossRefGoogle Scholar
  11. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001, 22: 718–31.PubMedGoogle Scholar
  12. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in men. N Engl J Med 1996, 335: 1–7.PubMedCrossRefGoogle Scholar
  13. Bhasin S, Storer TW, Berman N, et al. A replacement dose of testosterone increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997, 82: 407–13.PubMedGoogle Scholar
  14. Bhasin S, Storer TW, Javanbakht M, et al. Effects of testosterone replacement and resistance exercise on muscle strength, and body composition in human immunodeficiency virus-infected men with weight loss and low testosterone levels. JAMA 2000, 283: 763–70.PubMedCentralPubMedCrossRefGoogle Scholar
  15. Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testosterone replacement with a non-genital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998, 83: 3155–62.PubMedGoogle Scholar
  16. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2000, 281: E1172–81.Google Scholar
  17. Bhasin S, Woodhouse L, Storer TW. Proof of the effect of testosterone on skeletal muscle. J Endocrinol 2001, 170: 27–38.PubMedCrossRefGoogle Scholar
  18. Bonjour J-P, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femora bone mass and accumulation during adolescence. J Clin Endocrinol Metab 1991, 73: 555–63.PubMedCrossRefGoogle Scholar
  19. Boonen S, Vanderschueren D, Cheng XG, et al. Age-reated (type II) femoral neck osteoporosis in men: biochemical evidence for both hypovitaminosis D and androgen deficiency-induced bone resorption. J Bone Miner Res 1997, 12: 2119–26.PubMedCrossRefGoogle Scholar
  20. Boonen S, Vanderscheren D, Geusens P, Bouillon R. Age-associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men. Int J Androl 1997, 20: 134–43.PubMedCrossRefGoogle Scholar
  21. Borkan GA, Hults DE, Gerzof SG, Robbins AH, Silbert CK. Age changes in body composition revealed by computed tomography. J Gerontol 1983, 38: 673–7.PubMedCrossRefGoogle Scholar
  22. Brodsky IG, Balagopal P, Nair KS Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men-a Clinical Research Center Study. J Clin Endocrinol Metab 1996, 81: 3469–75.PubMedGoogle Scholar
  23. Bross R, Casaburi R, Storer TW, Bhasin S. Androgen effects on body composition and muscle function: implications for the use of androgens as anabolic agents in sarcopenic states. Baillieres Clin Endocrinol Metab 1998, 12: 365–78.PubMedCrossRefGoogle Scholar
  24. Casaburi R, Goren S, Bhasin S. Substantial prevalence of low anabolic hormone levels in COPD patients undergoing rehabilitation. Am J Respir Crit Care Med 1996, 153: A128.CrossRefGoogle Scholar
  25. Casaburi R, Storer T, Bhasin S. Androgen effects on body composition and muscle performance. In: Bhasin S, Gabelnick H, Spieler JM, Swerdloff RS, Wang C eds. Pharmacology, biology, and clinical applications of androgens: current status and future prospects. New York: Wiley-Liss. 1996, 283–288Google Scholar
  26. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in man with aromatase deficiency. N Engl J Med 1997, 337: 91–5.PubMedCrossRefGoogle Scholar
  27. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353: 878–82.PubMedCrossRefGoogle Scholar
  28. Colvard DS, Eriksen EF, Keeting PE, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 1989, 86: 854–7.PubMedCentralPubMedCrossRefGoogle Scholar
  29. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss. AIDS 1997, 11: 1347–52.PubMedCrossRefGoogle Scholar
  30. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997 157: 439–44.PubMedCrossRefGoogle Scholar
  31. Dobs A, Cofrancesco J, Nolten WE, et al. The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 1999, 107: 126–32.PubMedCrossRefGoogle Scholar
  32. Ellis KJ. Human body composition: in vivo methods. Physiol Rev 2000, 80: 649–80.PubMedGoogle Scholar
  33. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone minera density in patients with prostate cancer treated with orchiectomy and with estrogens. Calcif Tissue Int 1995, 57: 97–9.PubMedCrossRefGoogle Scholar
  34. Finkelstein JS, Klibanski A, Neer RM, Grrenspan SL, Rosenthal DI, Crowley Jr WF. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987, 106: 354–61.PubMedCrossRefGoogle Scholar
  35. Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA 1998, 95: 6965–70.PubMedCentralPubMedCrossRefGoogle Scholar
  36. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002, 282: E601–7.PubMedGoogle Scholar
  37. Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H. Decreased bone mineral density in elderly men treated with gonadortropin-releaasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993, 76: 288–90.PubMedGoogle Scholar
  38. Goulding A, Gold E. Flutamide-mediated androgen blockade evokes osteopenia in the female rat. J Bone Miner Res 1993, 8: 763–9.PubMedCrossRefGoogle Scholar
  39. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997, 12: 1833–43.PubMedCrossRefGoogle Scholar
  40. Griggs RC, Kingston W, Josefowicz RF, Herr BE, Forbes G, Halliday D. Effect of testosterone on muscle mass and muscle protein synthesis. Journal of Applied Physiology 1989, 66: 498–503.PubMedGoogle Scholar
  41. Griggs RC, Pandya S, Florence JM, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 1989, 39: 219–22.PubMedCrossRefGoogle Scholar
  42. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen adminsitration in men with the AIDS wasting syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 129: 18–26.PubMedCrossRefGoogle Scholar
  43. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and ean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996, 81: 4358–65.PubMedGoogle Scholar
  44. Katznelson L, Rosenthal DI, Rosol MS, et al. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. Am J Roentgenol 1998, 170: 423–7.CrossRefGoogle Scholar
  45. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone evels. J Gerontol A Biol Sci Med Sci 2001, 56: M266–72.PubMedCrossRefGoogle Scholar
  46. Kenny AM, Gallagher JC, Prestwood KM, Gruman CA, Raisz LG. Bone density, bone turnover, and hormone levels in men over age 75. J Gerontol A Biol Sci Med Sci 1998, 53: M419–25.PubMedCrossRefGoogle Scholar
  47. Kenyon AT, Knowlton K, Sandiford I, Kock FC, Lotwin G. A comparative study of the metabolic effects of testosterone propionate in normal men and women and in eunuchoidism. Endocrinology 1940, 26: 26–45.CrossRefGoogle Scholar
  48. Knowlton K, Kenyon AT, Sandiford I, Lotwin G, Fricker R. Comparative study of metabolic effects of estradiol benzoate and testosterone propionate in men. J Clin Endocrinol Metab 1942, 2: 671–84.CrossRefGoogle Scholar
  49. Kochakian CD. Comparison of protein anabolic properties of various androgens in the castrated rat. Am J Physio 1950, 60: 553–8.Google Scholar
  50. Leifke E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebra body area and paraspinal muscle area in hypogonada men. Eur J Endocrinol 1998, 138: 51–8.PubMedCrossRefGoogle Scholar
  51. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle, and adipose tissues. Eur J Med 1992, 1: 329–36.PubMedGoogle Scholar
  52. Marin P, Oden B & Bjorntorp P 1995 Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995, 80: 239–43.PubMedGoogle Scholar
  53. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength and adiposity. J Clin Endocrino Metab 1998, 83: 1886.Google Scholar
  54. Melton LJ 3rd, Khosla S, Riggs BL. Epidemiology of sarcopenia. Mayo Clin Proc 2000, 75 (Suppl): S10–2; discussion S12–3.PubMedCrossRefGoogle Scholar
  55. Melton LJ III, Atkinson EJ, O’Connor MK, et al. Bone density and fracture risk in men. J Bone Mineral Res 1998, 13: 1915–23.CrossRefGoogle Scholar
  56. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002, 87: 5001–7.PubMedCrossRefGoogle Scholar
  57. Morley JE, Perry HM 3rd, Kaiser FE, e al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993, 41: 149–152.PubMedGoogle Scholar
  58. Morley JE, Kaiser F, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci 1997, 94: 7537–42.PubMedCentralPubMedCrossRefGoogle Scholar
  59. Nguyen TV, Sambrook PN, Eisman JA. Bone loss, physical activity, and weight change in elderly women: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 1998, 13: 1458–65.PubMedCrossRefGoogle Scholar
  60. Novak LP. Aging, total body potassium, fat free-mass, and cell mass in males and females between ages 18–85 years. J Gerontol 1972, 27: 438–43PubMedCrossRefGoogle Scholar
  61. Perry HM 3rd, Miller DK, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism 2000, 49: 1085–91.PubMedCrossRefGoogle Scholar
  62. Pirke KM, Doerr P. Age related changes and interrelationships between plasma testosterone, oestradiol and testosterone-binding globulin in normal adult males. Acta Endocrinol (Copenh) 1973, 74: 792–800.Google Scholar
  63. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997, 12: 24–35.PubMedCrossRefGoogle Scholar
  64. Roy TA, Blackman MR, Harman SM, Tobin JD, Schrager M, Metter EJ. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab 2002, 283: E284–94.PubMedGoogle Scholar
  65. Schols AMW, Soeters PB, Mostert R. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 152: 1268–74.PubMedCrossRefGoogle Scholar
  66. Seidell J, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels, but negatively with testosterone levels. Metabolism 1990, 39: 897–901.PubMedCrossRefGoogle Scholar
  67. Sheffield-Moore M, Urban RJ, Wolf SE, et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 1999, 84: 2705–11.PubMedGoogle Scholar
  68. Schroeder ET, Singh AB, Bhasin S, et al. The effects of different doses of an oral androgen on muscle and metabolism in community dwelling older men. Am J Physiol Endocrinol Metab 2002 (in press)Google Scholar
  69. Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial (see comments). J Clin Endocrinol Metab 1997, 82: 1661–7.PubMedCrossRefGoogle Scholar
  70. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002, 87: 136–43.PubMedCrossRefGoogle Scholar
  71. Sinha-Hilim I, Artaza J, Woodhouse L, et al. Testosteroneinduced increase in muscle size is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 2002, 283: E154–64.Google Scholar
  72. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65. J Clin Endocrinol Metab 1999, 84: 2647.PubMedGoogle Scholar
  73. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000, 85: 2670–7.PubMedGoogle Scholar
  74. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989, 69: 523–7.PubMedCrossRefGoogle Scholar
  75. Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991, 39: 766–71.PubMedGoogle Scholar
  76. Storer TW, Magliano L, Woodhouse L, Casaburi R, Bhasin S. Testosterone dose-dependently increases muscle strength and leg power, but not specific tension in healthy, young men. J Clin Endocrinol Metab 2003 (in press).Google Scholar
  77. Strawford A, Barbieri T, Neese R, et al. Effects of nandrolone decanoate therapy in borderline hypogonada men with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20: 137–46.PubMedCrossRefGoogle Scholar
  78. Strawford A, Barbieri T, Van Loan M, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. JAMA 1999, 281: 1282–90.PubMedCrossRefGoogle Scholar
  79. Taylor WE, Bhasin S, Singh R, Artaza J, Gonzalez-Cadavid NF. Testosterone promotes myogenesis in pluripotent mesenchymal cells. Endocrine Society Meeting, San Francisco, CA, June 18–22, 2002.Google Scholar
  80. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992, 75: 1092–8.PubMedGoogle Scholar
  81. Tenover JL. Experience with testosterone replacement in the elderly. Mayo Clin Proc 2000, 75 (Suppl): S77–81; discussion S82.PubMedGoogle Scholar
  82. Swerdloff RS, Wang C. Androgen deficiency and aging in men [see comments]. West J Med 1993, 159: 579–85.PubMedCentralPubMedGoogle Scholar
  83. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995, 269: E820–6.PubMedGoogle Scholar
  84. Vanderscheueren D, Van Herck E, Geusens P, et al. Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency. Endocrinology 1992, 130: 2906–16.Google Scholar
  85. Wang C, Eyre DR, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone resorption markers in hypogonadal men-a Clinical Research Center Study. J Clin Endocrinol Metab 1996, 81: 3654–62.PubMedGoogle Scholar
  86. Wang C, Swerdloff RS, Iranmanesh A, et al. Transderma testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000, 85: 2839–53.PubMedGoogle Scholar
  87. Wilson JD. Androgen abuse by athletes. Endocrin Rev 1988, 9: 181–99.CrossRefGoogle Scholar
  88. Wolfson L, Judge J, Whipple R, King, M. Strength is a major factor in balance, gait, and the occurrence of falls. J Gerontol 1995, 50A: 64–7.CrossRefGoogle Scholar
  89. Woodhouse L, Porsaszasz-Reisz S, Zerounian H, Javanbakht M, Lee M, Bhasin S. Development of models to predict anabolic response to testosterone in healthy, young men. Am J Physiol Endo Metab 2003 (in press).Google Scholar
  90. Wilson JD. Androgen abuse by athletes. Endocr Rev 1988, 9: 181–99.PubMedCrossRefGoogle Scholar
  91. Wilson JD. In: 1996 Goodman and Gilman’s “Pharmacologic Basis of Therapeutics”, 2000; 654–668.Google Scholar
  92. Wilson IB, Roubenoff R, Knox TA, Spiegleman D, Gorbach SL. Relation of lean body mass to health-related quality of ife in persons with HIV. J Acquir Immune Defic Syndr 2000, 24: 137–46.PubMedCrossRefGoogle Scholar
  93. Young NR, Baker HWG, Liu G, Seeman E. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. J Clin Endocrino Metab 1993, 77: 1028–32.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2003

Authors and Affiliations

  1. 1.UCLA School of Medicine, Division of Endocrinology, Metabolism, and Molecular MedicineCharles R. Drew University of Medicine and ScienceLos AngelesUSA

Personalised recommendations